Major therapeutic strategies in FRDA include development of agents to protect against oxidative damage and mitochondrial respiratory chain defects or agents that increase cellular frataxin expression, since cells lacking frataxin can be rescued through frataxin expression [8]. Here, FXN is linked to Friedreich ataxia.